Through 20 years of research and testing Vivadju have created a unique, patented DNA reagent which in combination with retinoic acid prevents cancer progression in at least 6 different mouse cancer models: breast cancer, 2 different colon cancers and two different liquid cancers (myelodysplastic syndromes and 2 types of acute myelogenous leukemia). It also has the potential for application in other cancers. This approach will use the patient’s own antibodies to kill cancer cells, which means the patient will not need to be subjected to radiation and chemotherapy. As a result, the patient will experience fewer side effects and an improved quality of life. pVAX14 also generates immunological memory, and unlike other therapies, the protective effect is longer term (up to the 2-year lifetime of the mice in which they have been tested). Potentially, the crucial combination with other agents could provide higher cure rates, prevent relapse and therefore save millions of lives.